Business
Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results
Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today reported financial results for the first quarter ended March 31, 2026, and provided a business and clinical update.
About this update from Protalix Biotherapeutics, Inc. (de)
[{"type":"text","content":"Company to host conference call and webcast today at 8:00 a.m. EDT","length":66,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen; $25 million milestone received from Chiesi","length":172,"tagName":"p"}]},{"val":[{"type":"text","content":"PRX–115 Phase 2 study continues to advance as planned with top–line results anticipated in the second half of 2027","length":114,"tagName":"p"}]},{"val":[{"type":"text","content":"The Company reaffirms its previously stated 2026 revenue guidance of $78.0 – $83.0 million including the $25.0 million milestone received from Chiesi","length":154,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash, cash equivalents, and short–term bank deposits were $51 million as of March 31, 2026, providing sufficient capital to fund ongoing operations including the Phase 2 RELEASE clinical trial of PRX-115","length":203,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":643,"olType":false},{"type":"text","content":"CARMIEL, Israel, May 13, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today reported financial results for the first quarter ended March 31, 2026, and provided a business and clinical update.","length":396,"tagName":"p"},{"type":"image","alt":"Protalix BioTherapeutics, Inc. Logo","displaySize":"","headline":null,"caption":"Protalix BioTherapeutics, Inc. Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":121,"url":"https://media.zenfs.com/en/prnewswire.com/f2174d5c59bc5e34e9e5ea6a94c7eeba"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JqTp0X7VmxnrsXQUFDueUg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIxMztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/f2174d5c59bc5e34e9e5ea6a94c7eeba","width":400,"height":121},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/yFBmhSX15CEsUTAwZ1Md2g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTE5NDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/f2174d5c59bc5e34e9e5ea6a94c7eeba","width":400,"height":121}}},{"type":"text","content":"During the firs...